Business
Scotland NHS “test of change” pilot programme
Genedrive plc has announced the implementation of its CYP2C19 ID Kit into NHS Grampian and NHS Western Isles for a one-year "test of change" pilot program involving approximately 400 stroke patients in remote and rural settings. This initiative, supported by the Scottish Government's Centre For Sustainable Delivery, aims to assess the impact of rapid genetic testing compared to current laboratory-based pathways, potentially leading to a precision medicine approach for antiplatelet therapy and improved patient outcomes. The company is confident this pilot will strengthen the case for wider deployment of its rapid testing solution across Scotland. Disclaimer*
About this update from Genedrive Plc
[{"type":"text","content":"\n\ngenedrive plc\n(\"genedrive\" or the \"Company\")\n \nGenedrive's CYP2C19 ID kit piloted as a \"test of change\" in Scotland NHS Grampian and Western Isles\n \ngenedrive plc (AIM: GDR), the point of care pharmacogenetic testing company, announces that Genedrive's CYP2C19 ID Kit has been implemented into Scottish NHS Grampian (Dr. Gray's Hospital, Elgin) & NHS Western Isles (Western Isles Hospital, Stornoway) under a \"test of change\" pilot programme for stroke patients in remote and rural settings.\n \nWhilst the pathway for CYP2C19 genotyping in NHS Scotland currently relies on laboratory testing, the Centre For Sustainable Delivery, commissioned by the Scottish Government, are assessing the impact of rapid genetic testing using the Genedrive CYP2C19 ID kit under a \"test of change\" programme which will run for approximately one year and include c.400 patients.\n \nFurther details are available at https://shorturl.at/P4i00\n \n \nDr Gino Miele, CEO of genedrive plc, said: \"We are delighted that the Centre for Sustainable Delivery is assessing the impact of our interventional rapid genetic test solution in NHS Grampian and Western Isles, enabling a precision medicine approach to antiplatelet therapy in these stroke patients in rural settings, and ultimately, significantly better outcomes for patients in these communities. Whilst a relatively small \"pilot\" programme, it is notable that our interventional test is being explored as a \"test of change\" and we are confident that the clinical value of our rapid testing solution will continue to be evident and the case for wider deployment in Scotland strengthened.\"\n \nNHS Grampian consultant in stroke/acute medicine and clinical lead for the project, Petrus Elofuke, said: \"We are introducing the Genedrive® CYP2C19 ID Kit test as a test of change in Elgin and Stornoway at the same time as samples are sent for lab-based testing. We'll look at how results compare over the next year. It's the first time a device of this kind has been tested in remote and rural settings, and we're extremely proud to be working with colleagues across the two health boards as well as the national Centre for Sustainable Delivery.\"\n \nClinical lead for the project in NHS Western Isles, David Rigby said: \"If the devices deliver proven result...